{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:05:22Z","timestamp":1790460322142,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,5,1]]},"DOI":"10.1038\/sj.leu.2402890","type":"journal-article","created":{"date-parts":[[2003,5,15]],"date-time":"2003-05-15T17:50:08Z","timestamp":1053021008000},"page":"900-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct"],"prefix":"10.1038","volume":"17","author":[{"given":"A","family":"L\u00f6ffler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gruen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Wuchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Schriever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Dreier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Hanakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Baeuerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bommert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Karawajew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"D\u00f6rken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R C","family":"Bargou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,5,15]]},"reference":[{"key":"BF2402890_CR1","first-page":"8","volume":"49","author":"SH Landis","year":"1999","unstructured":"Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1999. CA: Cancer J Clin 1999; 49: 8\u201331, 31.","journal-title":"CA: Cancer J Clin"},{"key":"BF2402890_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","volume":"93","author":"A \u00d6sterborg","year":"1996","unstructured":"\u00d6sterborg A, Fassas AS, Anagnostopoulos A, Dyer MJS . Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukemia. Br J Haematol 1996; 93: 151\u2013153.","journal-title":"Br J Haematol"},{"key":"BF2402890_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A \u00d6sterborg","year":"1997","unstructured":"\u00d6sterborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567\u20131574.","journal-title":"J Clin Oncol"},{"key":"BF2402890_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1040-8428(00)00069-X","volume":"37","author":"S Sacchi","year":"2001","unstructured":"Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo V et al. Treatment of B-cell non-Hodgkin's lymphoma with anti-CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol 2001; 37: 13\u201325.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF2402890_CR5","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188\u20132195.","journal-title":"Blood"},{"key":"BF2402890_CR6","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","volume":"98","author":"D Huhn","year":"2001","unstructured":"Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R et al. Rituximab in the treatment of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326\u20131331.","journal-title":"Blood"},{"key":"BF2402890_CR7","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A . Cytokine-release syndrome in patients with B-Cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 1999; 94: 2217\u20132224.","journal-title":"Blood"},{"key":"BF2402890_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443\u2013446.","journal-title":"Nat Med"},{"key":"BF2402890_CR9","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood.V73.6.1431.1431","volume":"73","author":"MJ Dyer","year":"1989","unstructured":"Dyer MJ, Hale G, Hayhoe FG, Waldmann H . Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431\u20131439.","journal-title":"Blood"},{"key":"BF2402890_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0167-5699(00)01659-5","volume":"21","author":"AB van Spriel","year":"2000","unstructured":"van Spriel AB, van Ojik HH, van De Winkel JG . Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000; 21: 391\u2013397.","journal-title":"Immunol Today"},{"key":"BF2402890_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3109\/10428199509049758","volume":"16","author":"GJ Weiner","year":"1995","unstructured":"Weiner GJ, De Gast GC . Bispecific monoclonal antibody therapy of B-cell malignancy. Leukemia Lymphoma 1995; 16: 199\u2013207.","journal-title":"Leukemia Lymphoma"},{"key":"BF2402890_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0167-5699(94)90274-7","volume":"15","author":"TF Tedder","year":"1994","unstructured":"Tedder TF, Zhou LJ, Engel P . The CD19\/CD21 signal transduction complex of B lymphocytes. Immunol Today 1994; 15: 437\u2013442.","journal-title":"Immunol Today"},{"key":"BF2402890_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","volume":"6","author":"TF Tedder","year":"1997","unstructured":"Tedder TF, Inaoki M, Sato S . The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6: 107\u2013118.","journal-title":"Immunity"},{"key":"BF2402890_CR14","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1182\/blood.V87.10.4390.bloodjournal87104390","volume":"87","author":"C Demanet","year":"1996","unstructured":"Demanet C, Brissinck J, De Jonge J, Thielemans K . Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 1996; 87: 4390\u20134398.","journal-title":"Blood"},{"key":"BF2402890_CR15","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1182\/blood.V85.11.3208.bloodjournal85113208","volume":"85","author":"IA Haagen","year":"1995","unstructured":"Haagen IA, Geerars AJ, de Lau WB, Bast BJ, De Gast BC . The efficacy of CD3 \u00d7 CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood 1995; 85: 3208\u20133212.","journal-title":"Blood"},{"key":"BF2402890_CR16","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood.V96.10.3544","volume":"96","author":"J Honeychurch","year":"2000","unstructured":"Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ . Therapeutic efficacy of FcgammaRI\/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 2000; 96: 3544\u20133552.","journal-title":"Blood"},{"key":"BF2402890_CR17","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1182\/blood.V92.12.4750","volume":"92","author":"PT Daniel","year":"1998","unstructured":"Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, D\u00f6rken B et al. Immunotherapy of B-cell lymphoma with CD3 \u00d7 19 bispecific antibodies: costimulation via CD28 prevents \u2018veto\u2019 apoptosis of antibody-targeted cytotoxic T cells. Blood 1998; 92: 4750\u20134757.","journal-title":"Blood"},{"key":"BF2402890_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/0140-6736(90)90205-J","volume":"335","author":"T Nitta","year":"1990","unstructured":"Nitta T, Sato K, Yagita H, Okumura K, Ishii S . Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335: 368\u2013371.","journal-title":"Lancet"},{"key":"BF2402890_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/jnci\/87.19.1463","volume":"87","author":"S Canevari","year":"1995","unstructured":"Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87: 1463\u20131469.","journal-title":"J Natl Cancer Inst"},{"key":"BF2402890_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/scd.1.1995.4.433","volume":"4","author":"GC De Gast","year":"1995","unstructured":"De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A et al. Clinical experience with CD3 \u00d7 CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 1995; 4: 433\u2013437.","journal-title":"J Hematother"},{"key":"BF2402890_CR21","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.V89.6.2042","volume":"89","author":"F Hartmann","year":"1997","unstructured":"Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B et al. Treatment of refractory Hodgkin's disease with an anti-CD16\/CD30 bispecific antibody. Blood 1997; 89: 2042\u20132047.","journal-title":"Blood"},{"key":"BF2402890_CR22","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1182\/blood-2001-12-0295","volume":"100","author":"P Borchmann","year":"2002","unstructured":"Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD et al. Phase 1 trial of the novel bispecific molecule H22 \u00d7 Ki-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100: 3101\u20133107.","journal-title":"Blood"},{"key":"BF2402890_CR23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.4049\/jimmunol.148.5.1547","volume":"148","author":"SA Kostelny","year":"1992","unstructured":"Kostelny SA, Cole MS, Tso JY . Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148: 1547\u20131553.","journal-title":"J Immunol"},{"key":"BF2402890_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/eji.1830170118","volume":"17","author":"A Lanzavecchia","year":"1987","unstructured":"Lanzavecchia A, Scheidegger D . The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1987; 17: 105\u2013111.","journal-title":"Eur J Immunol"},{"key":"BF2402890_CR25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0021-9258(17)42334-9","volume":"269","author":"WD Mallender","year":"1994","unstructured":"Mallender WD, Voss EJ . Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994; 269: 199\u2013206.","journal-title":"J Biol Chem"},{"key":"BF2402890_CR26","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler A, Kufer P, Lutterb\u00fcse R, Zettl F, Daniel PT, Schwenkenbecher JM et al. A recombinant bispecific single-chain antibody, CD19 \u00d7 CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95: 2098\u20132103.","journal-title":"Blood"},{"key":"BF2402890_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690\u2013697.","journal-title":"Int J Cancer"},{"key":"BF2402890_CR28","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/sj.leu.2402127","volume":"15","author":"M Blagosklonny","year":"2001","unstructured":"Blagosklonny M . Treatment with inhibitors of caspases that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001; 15: 936\u2013941.","journal-title":"Leukemia"},{"key":"BF2402890_CR29","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","volume":"92","author":"M Mack","year":"1995","unstructured":"Mack M, Riethm\u00fcller G, Kufer P . A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92: 7021\u20137025.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402890_CR30","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1074\/jbc.M106699200","volume":"277","author":"SH Kwon","year":"2001","unstructured":"Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas\/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2001; 277: 2073\u20132080.","journal-title":"J Biol Chem"},{"key":"BF2402890_CR31","first-page":"6259","volume":"60","author":"N Ozoren","year":"2000","unstructured":"Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS . The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000; 60: 6259\u20136265.","journal-title":"Cancer Res"},{"key":"BF2402890_CR32","first-page":"1138","volume":"61","author":"DW Seol","year":"2001","unstructured":"Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR . Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 2001; 61: 1138\u20131143.","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"BF2402890_CR33","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1038\/sj.bmt.1702355","volume":"26","author":"H Tesch","year":"2000","unstructured":"Tesch H, Engert A, Manzke O, Diehl V, Bohlen H . Treatment of patients with malignant lymphomas with monoclonal antibodies. Bone Marrow Transplant 2000; 26(Suppl 2): S50\u2013S53.","journal-title":"Bone Marrow Transplant"},{"key":"BF2402890_CR34","first-page":"79","volume":"27","author":"SP Treon","year":"2000","unstructured":"Treon SP, Anderson KC . The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27: 79\u201385.","journal-title":"Semin Oncol"},{"key":"BF2402890_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V67.2.279.279","volume":"67","author":"O Ayanlar-Batuman","year":"1986","unstructured":"Ayanlar-Batuman O, Ebert E, Hauptman SP . Defective inter-leukin-2 production and responsiveness by T cells in patients with chronic lymphocytic leukemia of B cell variety. Blood 1986; 67: 279\u2013284.","journal-title":"Blood"},{"key":"BF2402890_CR36","first-page":"27","volume":"25","author":"MM Bartik","year":"1998","unstructured":"Bartik MM, Welker D, Kay NE . Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998; 25: 27\u201333.","journal-title":"Semin Oncol"},{"key":"BF2402890_CR37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V67.3.578.578","volume":"67","author":"NE Kay","year":"1986","unstructured":"Kay NE, Kaplan ME . Defective T cell responsiveness in chronic lymphocytic leukemia: analysis of activation events. Blood 1986; 67: 578\u2013581.","journal-title":"Blood"},{"key":"BF2402890_CR38","first-page":"1563","volume":"21","author":"A Prieto","year":"1993","unstructured":"Prieto A, Garcia-Suarez J, Reyes E, Lapena P, Hernandez M, Alvarez-Mon M . Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals. Exp Hematol 1993; 21: 1563\u20131569.","journal-title":"Exp Hematol"},{"key":"BF2402890_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0268-960X(90)90044-S","volume":"4","author":"SL Zaknoen","year":"1990","unstructured":"Zaknoen SL, Kay NE. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev 1990; 4: 165\u2013174.","journal-title":"Blood Rev"},{"key":"BF2402890_CR40","first-page":"5968","volume":"59","author":"A Shimoni","year":"1999","unstructured":"Shimoni A, Marcus H, Dekel B, Shkarchi R, Arditti F, Shvidel L et al. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human--&gt;mouse radiation chimera. Cancer Res 1999; 59: 5968\u20135974.","journal-title":"Cancer Res"},{"key":"BF2402890_CR41","first-page":"589a","volume":"99","author":"S Natarajan","year":"1996","unstructured":"Natarajan S, Kay NE, Yannelli JR . In vitro propagation of anti-tumor lymphocytes derived from the peripheral blood mononuclear cells of patients with B-chronic lymphocytic leukemia. Blood 1996; 99: 589a.","journal-title":"Blood"},{"key":"BF2402890_CR42","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135\u20133143.","journal-title":"J Clin Oncol"},{"key":"BF2402890_CR43","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"BF2402890_CR44","first-page":"4310","volume":"53","author":"H Bohlen","year":"1993","unstructured":"Bohlen H, Manzke O, Patel B, Moldenhauer G, D\u00f6rken B, von Fliedner V et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993; 53: 4310\u20134314.","journal-title":"Cancer Res"},{"key":"BF2402890_CR45","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<715::AID-IJC15>3.0.CO;2-P","volume":"80","author":"O Manzke","year":"1999","unstructured":"Manzke O, Berthold F, Huebel K, Tesch H, Diehl V, Bohlen H . CD3 \u00d7 CD19 bispecific antibodies and CD28 bivalent antibodies enhance T- cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int J Cancer 1999; 80: 715\u2013722.","journal-title":"Int J Cancer"},{"key":"BF2402890_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2249.1992.tb05853.x","volume":"90","author":"IA Haagen","year":"1992","unstructured":"Haagen IA, van de Griend R, Clark M, Geerars A, Bast B, de Gast B . Killing of human leukaemia\/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3\/alpha CD19). Clin Exp Immunol 1992; 90: 368\u2013375.","journal-title":"Clin Exp Immunol"},{"key":"BF2402890_CR47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.V84.2.556.556","volume":"84","author":"IA Haagen","year":"1994","unstructured":"Haagen IA, Geerars AJ, de Lau WB, Clark MR, van de Griend RJ, Bast BJ et al. Killing of autologous B-lineage malignancy using CD3 \u00d7 CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 1994; 84: 556\u2013563.","journal-title":"Blood"},{"key":"BF2402890_CR48","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4049\/jimmunol.165.2.888","volume":"165","author":"B Cochlovius","year":"2000","unstructured":"Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuhmacher J, Strauss G et al. Treatment of human B cell lymphoma xenografts with a CD3 \u00d7 CD19 diabody and T cells. J Immunol 2000; 165: 888\u2013895.","journal-title":"J Immunol"},{"key":"BF2402890_CR49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.V96.2.594","volume":"96","author":"C Lehmann","year":"2000","unstructured":"Lehmann C, Zeis M, Schmitz N, Uharek L . Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000; 96: 594\u2013600.","journal-title":"Blood"},{"key":"BF2402890_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s002620050428","volume":"45","author":"C Renner","year":"1997","unstructured":"Renner C, Hartmann F, Pfreundschuh M . Treatment of refractory Hodgkin's disease with an anti-CD16\/CD30 bispecific antibody. Cancer Immunol Immunother 1997; 45: 184\u2013186.","journal-title":"Cancer Immunol Immunother"},{"key":"BF2402890_CR51","first-page":"1961","volume":"59","author":"S Bauer","year":"1999","unstructured":"Bauer S, Renner C, Juwana JP, Held G, Ohnesorge S, Gerlach K et al. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res 1999; 59: 1961\u20131965.","journal-title":"Cancer Res"},{"key":"BF2402890_CR52","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.immunol.20.100201.131730","volume":"20","author":"JH Russell","year":"2002","unstructured":"Russell JH, Ley TJ . Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323\u2013370.","journal-title":"Annu Rev Immunol"},{"key":"BF2402890_CR53","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.4049\/jimmunol.165.6.3023","volume":"165","author":"A Hennino","year":"2000","unstructured":"Hennino A, Berard M, Casamayor-Palleja M, Krammer PH, Defrance T . Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J Immunol 2000; 165: 3023\u20133030.","journal-title":"J Immunol"},{"key":"BF2402890_CR54","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1128\/MCB.20.11.3781-3794.2000","volume":"20","author":"M Barry","year":"2000","unstructured":"Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR et al. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol 2000; 20: 3781\u20133794.","journal-title":"Mol Cell Biol"},{"key":"BF2402890_CR55","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1074-7613(00)80213-7","volume":"12","author":"DA Thomas","year":"2000","unstructured":"Thomas DA, Du C, Xu M, Wang X, Ley TJ . DFF45\/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 2000; 12: 621\u2013632.","journal-title":"Immunity"},{"key":"BF2402890_CR56","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1046\/j.1365-2141.1999.01642.x","volume":"106","author":"S Kitada","year":"1999","unstructured":"Kitada S, Zapata JM, reeff M, Reed JC . Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995\u20131004.","journal-title":"Br J Haematol"},{"key":"BF2402890_CR57","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood.V98.9.2800","volume":"98","author":"DT Jones","year":"2001","unstructured":"Jones DT, Ganeshaguru K, Virchis AE, Folarin NI, Lowdell MW, Mehta AB et al. Caspase 8 activation independent of Fas (CD95\/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 2001; 98: 2800\u20132807.","journal-title":"Blood"},{"key":"BF2402890_CR58","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0145-2126(01)00063-7","volume":"25","author":"G Roue","year":"2001","unstructured":"Roue G, Lancry L, Duquesne F, Salaun V, Troussard X, Sola B . Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia. Leukemia Res 2001; 25: 967\u2013980.","journal-title":"Leukemia Res"},{"key":"BF2402890_CR59","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1034\/j.1600-0609.2001.066005342.x","volume":"66","author":"LM Osorio","year":"2001","unstructured":"Osorio LM, Aguilar-Santelises M, De Santiago A, Hachiya T, Mellstedt H, Jondal M . Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol 2001; 66: 342\u2013346.","journal-title":"Eur J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402890","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402890.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T08:33:40Z","timestamp":1682498020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5,1]]}},"alternative-id":["BF2402890"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402890","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,1]]},"assertion":[{"value":"5 March 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}